The estimated Net Worth of Michael T. Andriole is at least $1.89 Million dollars as of 8 August 2024. Mr. Andriole owns over 1,285 units of Chimerix Inc stock worth over $397,710 and over the last 8 years he sold CMRX stock worth over $281,684. In addition, he makes $1,206,600 as Chief Financial Officer and Chief Business Officer at Chimerix Inc.
Sign up
Mr. Andriole CMRX stock SEC Form 4 insiders trading
Michael has made over 9 trades of the Chimerix Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,285 units of CMRX stock worth $1,067 on 8 August 2024.
The largest trade he's ever made was buying 100,000 units of Chimerix Inc stock on 6 November 2019 worth over $156,000. On average, Michael trades about 14,093 units every 102 days since 2017. As of 8 August 2024 he still owns at least 462,453 units of Chimerix Inc stock.
You can see the complete history of Mr. Andriole stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Andriole biography
Michael T. Andriole is the Chief Financial Officer, Chief Business Officer of the Company. Prior to joining the Company, Mr. Andriole served as the Chief Financial Officer of Endocyte, a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer, from February 2017 until its acquisition by Novartis AG in December 2018. From June 2001 to February 2017, Mr. Andriole served in various executive roles at Eli Lilly and Company, a large pharmaceutical company that develops, manufactures and markets pharmaceutical products on a global basis, and most recently as Vice President, Corporate Business Development from December 2014 to February 2017. Previous roles included Director, European Development and Strategic Planning and Director, Corporate Finance and Investment Banking. Mr. Andriole holds a B.S. in Finance from Xavier University’s Williams College of Business and an M.B.A. from Kelley School of Business, Indiana University.q
What is the salary of Michael Andriole?
As the Chief Financial Officer and Chief Business Officer of Chimerix Inc, the total compensation of Michael Andriole at Chimerix Inc is $1,206,600. There are 1 executives at Chimerix Inc getting paid more, with Michael Sherman having the highest compensation of $2,644,630.
How old is Michael Andriole?
Michael Andriole is 47, he's been the Chief Financial Officer and Chief Business Officer of Chimerix Inc since 2019. There are 11 older and 1 younger executives at Chimerix Inc. The oldest executive at Chimerix Inc is Catherine Gilliss, 71, who is the Independent Director.
What's Michael Andriole's mailing address?
Michael's mailing address filed with the SEC is 2505 MERIDIAN PARKWAY, SUITE 100, , DURHAM, NC, 27713.
Insiders trading at Chimerix Inc
Over the last 11 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex, and Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
What does Chimerix Inc do?
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
What does Chimerix Inc's logo look like?
Complete history of Mr. Andriole stock trades at Chimerix Inc
Chimerix Inc executives and stock owners
Chimerix Inc executives and other stock owners filed with the SEC include:
-
Michael Sherman,
President, Chief Executive Officer, Director -
Michael Andriole,
Chief Financial Officer, Chief Business Officer -
Michael Alrutz,
Senior Vice President, General Counsel -
Michael A. Sherman,
CEO, Pres & Director -
Michael T. Andriole M.B.A.,
Chief Bus. Officer, Sec. & CFO -
Dr. Allen S. Melemed M.B.A., M.D.,
Chief Medical Officer -
Martha Demski,
Independent Chairman of the Board -
Patrick Machado,
Independent Director -
Fred Middleton,
Independent Director -
Robert Meyer,
Independent Director -
Catherine Gilliss,
Independent Director -
Edward Greissing,
Independent Director -
Pratik Multani,
Independent Director -
Dr. Joshua E. Allen,
Chief Technology Officer of Imipridones -
Dr. Michael A. Alrutz,
Sr. VP, Gen. Counsel & Corp. Sec. -
Michelle LaSpaluto,
VP of Strategic Planning & Investor Relations -
Dr. Randall Lanier,
Chief Science Officer -
Dr. Roy W. Ware,
Chief Manufacturing & Technology Officer -
David Jakeman,
Exec. Director of Fin. & Accounting and Principal Accounting Officer -
Michael D. Rogers,
Chief Development Officer -
James Niedel,
Director -
Ernest Mario,
Director -
M Michelle Berrey,
President and CEO -
Garrett Nichols,
Chief Medical Officer -
John M Leonard,
Director -
Ronald C Jr Renaud,
Director -
James M Daly,
Director -
Lisa Ricciardi,
Director -
Timothy Wollaeger,
Director -
Linda M Richardson,
Chief Commercial Officer -
Ed Greissing,
Director -
Victoria Vakiener,
-
Leaf Ventures Ii, L.P. New,
10% owner -
Venture Partners V, Lp Sand...,
10% owner -
Venture Partners Vi Co Inve...,
10% owner -
Rodman L Drake,
Director -
Vii L P Canaan Partners Vii...,
-
Leaf Ventures Ii, L.P.New L...,
-
Kenneth I Moch,
President and CEO -
Wende S Hutton,
Director -
Venture Partners V, Lp Sand...,
-
Arthur M Pappas,
Director -
Venture Partners V, Lpsande...,
-
Farah Champsi,
Director -
Timothy W. Trost,
SVP, CFO & Secretary -
Biopharma Partners Iii Lpal...,
-
Pappas Life Science Venture...,
-
Lisa Lynn Decker,
-
Pharmaceuticals, Inc. Cantex,
10% owner -
Marc D Kozin,
-
David Jakeman,
VP OF FINANCE AND ACCOUNTING -
Thomas J Riga,
COO and CCO -
Allen S. Melemed,
CHIEF MEDICAL OFFICER -
Michelle La Spaluto,
CHIEF FINANCIAL OFFICER